These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12832104)

  • 1. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.
    Doyle ME; Theodorakis MJ; Holloway HW; Bernier M; Greig NH; Egan JM
    Regul Pept; 2003 Jul; 114(2-3):153-8. PubMed ID: 12832104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
    Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
    J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
    Al-Sabah S; Donnelly D
    Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
    Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
    Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
    López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
    J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
    Swedberg JE; Schroeder CI; Mitchell JM; Fairlie DP; Edmonds DJ; Griffith DA; Ruggeri RB; Derksen DR; Loria PM; Price DA; Liras S; Craik DJ
    J Biol Chem; 2016 Jul; 291(30):15778-87. PubMed ID: 27226591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
    Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
    West GM; Willard FS; Sloop KW; Showalter AD; Pascal BD; Griffin PR
    PLoS One; 2014; 9(9):e105683. PubMed ID: 25180755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
    Runge S; Thøgersen H; Madsen K; Lau J; Rudolph R
    J Biol Chem; 2008 Apr; 283(17):11340-7. PubMed ID: 18287102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression.
    Wu Z; Liu S; Nair I; Omori K; Scott S; Todorov I; Shively JE; Conti PS; Li Z; Kandeel F
    Theranostics; 2014; 4(8):770-7. PubMed ID: 24955138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
    Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
    López de Maturana R; Treece-Birch J; Abidi F; Findlay JB; Donnelly D
    Protein Pept Lett; 2004 Feb; 11(1):15-22. PubMed ID: 14965274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
    Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
    Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and purification of exendin-4 dimer in Escherichia coli and its interaction with GLP-1 receptor in vitro.
    Yi L; Yin X; Wei D; Ma Y
    Protein Pept Lett; 2006; 13(8):823-7. PubMed ID: 17073729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.